PURPOSE:Early-stage head and neck cancer patients are at high risks for tumor recurrence and secondary primary tumor (SPT) development. We hypothesized that latent genetic instability and proliferation potential may be associated with elevated risks of SPT and recurrence. EXPERIMENTAL DESIGN: We conducted a nested case-control study within a randomized, placebo-controlled chemoprevention trial in patients with early-stage head and neck cancer. We compared prediagnostic bleomycin-induced chromatid breaks in peripheral blood lymphocyte cultures (as an indicator of latent genetic instability) between 298 cases (patients with SPT/recurrence) and 693 controls (patients without SPT/recurrence). We also determined the joint effects of latent genetic instability and elevated proliferation potential [indicated by serum insulin-like growth factor (IGF) level] in modulating the risk of SPT and recurrence. RESULTS: In the Cox proportional hazards model, patients with higher mutagen sensitivity (using a cutoff of > or =0.50 breaks per cell) exhibited a significantly increased risk of developing SPT/recurrence [hazard ratio, 1.38; 95% confidence interval (95% CI), 1.02-1.86]. Cases also exhibited significantly higher levels of IGF-I and IGF-binding protein-3 than controls (P = 0.022 and 0.042, respectively). Moreover, there were joint effects between mutagen sensitivity and IGFs in modulating SPT/recurrence risk. Using patients with low IGF-I level and low mutagen sensitivity profile as the reference group, the odds ratios of developing SPT/recurrence for patients with high IGF-I level alone, high mutagen sensitivity alone, and both high IGF-I level and high mutagen sensitivity were 2.85 (95% CI, 0.92-8.82), 3.92 (95% CI, 1.28-11.97), and 6.16 (95% CI, 2.03-18.71), respectively. A similar joint effect was observed for mutagen sensitivity and IGF-binding protein-3 level. CONCLUSIONS: This is the largest prospective study to evaluate mutagen sensitivity as a prognosis marker in head and neck cancer because mutagen sensitivity data were derived from baseline samples drawn before the development of SPT or tumor recurrence. The results also show for the first time that latent genetic instability and elevated proliferation potential jointly elevate the risk of second tumors in early-stage head and neck cancers.
RCT Entities:
PURPOSE: Early-stage head and neck cancerpatients are at high risks for tumor recurrence and secondary primary tumor (SPT) development. We hypothesized that latent genetic instability and proliferation potential may be associated with elevated risks of SPT and recurrence. EXPERIMENTAL DESIGN: We conducted a nested case-control study within a randomized, placebo-controlled chemoprevention trial in patients with early-stage head and neck cancer. We compared prediagnostic bleomycin-induced chromatid breaks in peripheral blood lymphocyte cultures (as an indicator of latent genetic instability) between 298 cases (patients with SPT/recurrence) and 693 controls (patients without SPT/recurrence). We also determined the joint effects of latent genetic instability and elevated proliferation potential [indicated by serum insulin-like growth factor (IGF) level] in modulating the risk of SPT and recurrence. RESULTS: In the Cox proportional hazards model, patients with higher mutagen sensitivity (using a cutoff of > or =0.50 breaks per cell) exhibited a significantly increased risk of developing SPT/recurrence [hazard ratio, 1.38; 95% confidence interval (95% CI), 1.02-1.86]. Cases also exhibited significantly higher levels of IGF-I and IGF-binding protein-3 than controls (P = 0.022 and 0.042, respectively). Moreover, there were joint effects between mutagen sensitivity and IGFs in modulating SPT/recurrence risk. Using patients with low IGF-I level and low mutagen sensitivity profile as the reference group, the odds ratios of developing SPT/recurrence for patients with high IGF-I level alone, high mutagen sensitivity alone, and both high IGF-I level and high mutagen sensitivity were 2.85 (95% CI, 0.92-8.82), 3.92 (95% CI, 1.28-11.97), and 6.16 (95% CI, 2.03-18.71), respectively. A similar joint effect was observed for mutagen sensitivity and IGF-binding protein-3 level. CONCLUSIONS: This is the largest prospective study to evaluate mutagen sensitivity as a prognosis marker in head and neck cancer because mutagen sensitivity data were derived from baseline samples drawn before the development of SPT or tumor recurrence. The results also show for the first time that latent genetic instability and elevated proliferation potential jointly elevate the risk of second tumors in early-stage head and neck cancers.
Authors: Jianming Wang; Scott M Lippman; J Jack Lee; Hushan Yang; Fadlo R Khuri; Edward Kim; Jie Lin; David W Chang; Reuben Lotan; Waun K Hong; Xifeng Wu Journal: Carcinogenesis Date: 2010-07-12 Impact factor: 4.944
Authors: Xiaofan Zhang; Hushan Yang; J Jack Lee; Edward Kim; Scott M Lippman; Fadlo R Khuri; Margaret R Spitz; Reuben Lotan; Waun K Hong; Xifeng Wu Journal: Carcinogenesis Date: 2010-09-05 Impact factor: 4.944
Authors: Jian Gu; Yuanqing Ye; Margaret R Spitz; Jie Lin; Lambertus A Kiemeney; Jingliang Xing; Michelle A T Hildebrandt; Waun Ki Hong; Christopher I Amos; Xifeng Wu Journal: Hum Mol Genet Date: 2010-11-24 Impact factor: 6.150
Authors: Mark E Zafereo; Erich M Sturgis; Zhensheng Liu; Li-E Wang; Qingyi Wei; Guojun Li Journal: Carcinogenesis Date: 2009-04-15 Impact factor: 4.944
Authors: Xifeng Wu; Margaret R Spitz; J Jack Lee; Scott M Lippman; Yuanqing Ye; Hushan Yang; Fadlo R Khuri; Edward Kim; Jian Gu; Reuben Lotan; Waun K Hong Journal: Cancer Prev Res (Phila) Date: 2009-07
Authors: B Bukovszky; J Fodor; G Székely; S Zs Kocsis; F Oberna; T Major; Z Takácsi-Nagy; C Polgár; Z Jurányi Journal: Strahlenther Onkol Date: 2022-03-31 Impact factor: 4.033